|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||123.22 - 126.93|
|52 Week Range||75.72 - 174.65|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||72.53|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 09, 1992|
|1y Target Est||N/A|
In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness. Researchers at U.S.-based Editas Medicine (EDIT) and Ireland-based Allergan (now owned by AbbVie (ABBV) ) have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Shares of Gilead Sciences Inc. were down 1.2% in trading on Monday after the drugmaker said it plans to start Phase 1 clinical trials for an inhaled version of remdesivir, its treatment for severely ill COVID-19 patients. An intravenous version of the drug received an emergency use authorization from the Food and Drug Administration in May. The new study will first test this version of the investigational medication in healthy patients before moving on to COVID-19 patients. It is thought that an inhaled drug would be easier to administer outside of a hospital setting. "That could have significant implications in helping to stem the tide of the pandemic," CEO Daniel O'Day said in a letter on Monday. O'Day also said Gilead plans to test whether remdesivir can help patients before they become severely ill, in vulnerable patient populations like children and pregnant women, and in combination with other therapies, including Eli Lilly & Co. and Incyte Corp.'s Olumiant and Roche Holdings' Actemra. "We have been keen to explore how remdesivir might work when combined with anti-inflammatory agents, particularly in the most severely ill patients," he wrote. Gilead's stock is up 17.9% year-to-date, while the S&P 500 is down 4.1%.
Shares of Eli Lilly & Co. were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage trial assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-19. Olumiant, which was developed by Incyte Corp. and is licensed by Lilly, generated $426.9 million in revenue for Lilly in 2019. Several drugs developed to treat rheumatoid arthritis have become clinical targets in the hunt for COVID-19 treatments. This includes Olumiant, Roche Holdings' Actemra, and Regeneron Pharmaceuticals Inc. [: regn] and Sanofi 's Kevzara. The Phase 3 randomized, controlled clinical trial is testing Olumiant in hospitalized COVID-19 patients; it's expected to enroll 400 participants in the U.S., Europe, and Latin America, with an aim of reducing the cytokine storms that present in some of these patients. The National Institutes of Health is also conducting a trial evaluating Olumiant in combination with Gilead Sciences Inc.'s remdesivir. Lilly's stock has gained 9.2% year-to-date, while the S&P 500 is down 5.8%.
Shares of Roche Holding AG gained 2.4% in premarket trading on Thursday after the drugmaker said it is testing a combination of its rheumatoid arthritis drug Actemra with Gilead Sciences Inc.'s remdesivir in hospitalized COVID-19 patients. Gilead's stock was down 0.4%. Roche has previously announced it is studying Actemra in 450 hospitalized COVID-19 patients participating in a randomized, double-blind, placebo-controlled late-stage trial; results from that trial are expected "this summer," Roche said. The new Phase 3, randomized, double-blind, multicenter study will test Actemra and remdesivir against placebo and remdesivir in about 450 patients hospitalized with severe COVID-19 pneumonia. Trial sites are in Canada, Europe, and the U.S. The Food and Drug Administration granted an emergency use authorization to remdesivir on May 1 as a treatment for some severely ill COVID-19 patients. The experimental drug has not been approved as a treatment for the disease caused by the coronavirus. Since the start of the year, Roche's stock is up 8.2%, Gilead's stock has gained 15.2%, and the S&P 500 has declined 6.0%.
Today we are going to look at Rogers Corporation (NYSE:ROG) to see whether it might be an attractive investment...
The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.'s remdesivir in combination with Eli Lilly & Co.'s rheumatoid arthritis drug Olumiant in COVID-19 patients as part of the next phase of the randomized, controlled clinical trial that led to the authorization of remdesivir. This study will enroll 1,000 people at more than 100 sites in the U.S. and abroad, to "examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients," NIAID director Dr. Anthony Fauci said in a statement. The topline results from the remdesivir trial helped make up the basis of the Food and Drug Administration's (FDA) emergency use authorization for the drug last week. A number of medicines that have been previously approved by the FDA to treat rheumatoid arthritis have been proposed as possible COVID-19 treatments, including Regeneron Pharmaceuticals Inc. and Sanofi's Kevzara and Roche Holding AG's Actemra. Olumiant, which was developed by Incyte Corp. and is licensed to Lilly, brought in $427 million in sales in 2019 for the Indianapolis-based drugmaker. Only two types of therapies - remdesivir and hydroxycholorquine and chlorquine - are authorized by the FDA as COVID-19 treatments. Year-to-date, Gilead's stock has gained 18.6%, while shares of Lilly are up 16.6%. The S&P 500 is down 10.8%.
The Food and Drug Administration (FDA) on Monday changed its emergency-use policy for antibody tests, saying that manufacturers now have to seek regulatory authorization. The tests identify COVID-19 antibodies, which indicate a past infection with the novel coronavirus and are believed to provide some level of immunity to future infections; some experts say that widespread antibody testing is needed to reopen the economy. The FDA had announced on March 16 that antibody tests could be performed in some labs without an emergency use authorization (EUA), which is a type of regulatory OK granted during the pandemic. It is not an FDA approval. The makers of more than 200 tests have sought an EUA, and at least 12 have been granted one, including Abbott Laboratories Inc. and Roche Holding AG . But concerns about the quality and marketing claims for some tests that have not received an EUA created concern at the FDA. "The careful balancing of risks and benefits has shifted from where it was in mid-March," the regulator said. Test developers must now submit an EUA request with validation data within 10 days of an FDA notification, and these developers will follow a different submission template than the labs that are also developing antibody tests for authorization. "Flexibility never meant we would allow fraud," the FDA said Monday. "We, unfortunately, see unscrupulous actors marketing fraudulent test kits and using the pandemic as an opportunity to take advantage of Americans' anxiety." This includes claiming the tests are FDA approved or authorized, that they can be conducted at home, or can be used to diagnose COVID-19, according to the FDA. The regulator noted that all forms of antibody tests can produce false results, based on their "inherent limitations," and in some cases at least two antibody tests may need to be performed for one patient.
Rogers (NYSE:ROG) shareholders are no doubt pleased to see that the share price has bounced 33% in the last month...
Shares of Gilead Sciences Inc. gained 0.4% in trading on Monday after BMO Capital Markets downgraded the stock to market perform from outperform. Analysts there believe that despite [l: investor excitement about remdesivir, an experimental drug being tested as a treatment for COVID-19 patients, they "no longer see favorable risk/reward in shares given continued uncertainty around the remdesivir commercial opportunity." They wrote that progression of vaccines in development, which would prevent infection with the virus, raise questions about the durability of a post-infection treatment, noting that Roche AG's Tamiflu flu treatment generated more than $3 billion in revenue in 2009 during the H1N1 pandemic but sales of that drug brought in an average of $670 million annually after that. Year-to-date, Gilead's stock is up 29.6%, while the S&P 500 is down 11.0%.
The Swiss drug maker said the Elecsys Anti-Sars-CoV-2 immunoassay is an in-vitro test to detect antibodies and assess the body’s immune reaction to Sars-CoV-2, better known as Covid-19, using human serum and plasma from a blood sample.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
If you're interested in Rogers Corporation (NYSE:ROG), then you might want to consider its beta (a measure of share...
Rogers Corp. (ROG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While Rogers Corporation (NYSE:ROG) shareholders are probably generally happy, the stock hasn't had particularly good...